76 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
University Of Minnesota
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
Genomics Institute Of Novartis Research Foundation
Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.
Glaxosmithkline
Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.
Sumitomo Dainippon Pharma
Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
Dainippon Sumitomo Pharma
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
TBA
Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
University Of Kansas
Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.
University Of Kansas
Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.
University Of Kansas
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
Pfizer
Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7.
University Of Kansas
Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.
University Of Kansas
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
Dainippon Sumitomo Pharma
Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline.
University Of Kansas
Novel Triazatricycle Compounds for Treating Autoimmune Diseases.
Smith, Gambrell & Russell
Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.
Smith, Gambrell & Russell
Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.
Csir-Indian Institute Of Chemical Biology
Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.
University Of Kansas
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
Genomics Institute Of The Novartis Research Foundation
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Gilead Sciences
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.
Astrazeneca
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
University Of Montana
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
Princ
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Genomics Institute Of The Novartis Research Foundation
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
University Of Kansas
A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist.
Csir-Indian Institute Of Chemical Biology
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
University Of Colorado Boulder
Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
University Of Ljubljana
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
University Of Minnesota
Activity-guided development of potent and selective toll-like receptor 9 antagonists.
Csir-Indian Institute Of Chemical Biology
Toll-like Receptors for the Treatment of Autoimmune, Inflammation, and Infectious Diseases.
Usona Institute
Discovery of Novel Small-Molecule Inhibitors of NF-?B Signaling with Antiinflammatory and Anticancer Properties.
University Of Colorado
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
University Of Minnesota
Design and development of benzoxazole derivatives with toll-like receptor 9 antagonism.
Csir-Indian Institute Of Chemical Biology
Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
Janssen Pharmaceutica
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University Of Colorado Boulder
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
Yale University
Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2- and 5-HT2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2- and 5-HT2-receptors: comparison with ketanserin.
TBA
Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors.
TBA
Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.
Purdue University
Inhibition of adenosine deaminase by analogues of adenosine and inosine, incorporating a common heterocyclic base, 4(7)-amino-6(5)H-imidazo[4,5-d]pyridazin-7(4)one.
University Of Maryland Baltimore County
Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold.
Eli Lilly
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
Eli Lilly
Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1).
Pfizer
Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.
University Of Dundee
Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.
University Of Bologna